查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1967706

基因治療市場－全球產業規模、佔有率、趨勢、機會和預測：按載體類型、給藥方法、適應症、地區和競爭格局分類，2021-2031年

Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vector Type, By Delivery Method, By Indication, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球基因療法市場預計將從 2025 年的 75.4 億美元成長到 2031 年的 130.2 億美元，複合年成長率為 9.53%。

基因療法是指透過替換、惰性或導入患者細胞內的遺傳訊息（基因）來治療或預防疾病的醫療介入措施。這一市場成長的主要驅動力是罕見遺傳疾病和慢性病數量的不斷增加，這些疾病迫切需要永續的治療方案。此外，病毒載體技術的進步和法規核准流程的簡化正在加速核准進程，並促進從臨床研究到商業性化產品的轉化。

市場概覽
預測期 2027-2031
市場規模：2025年 75.4億美元
市場規模：2031年 130.2億美元
複合年成長率：2026-2031年 9.53%
成長最快的細分市場 非病毒載體
最大的市場 北美洲

儘管取得了這些進展，但高度複雜的生產流程和相關成本仍然是市場擴充性和普及化的重要障礙。這些經濟因素往往導致定價結構超越醫療保險報銷體系的承受能力，從而限制了病患獲得治療的機會。根據美國基因與細胞治療學會（ASGCT）統計，2025年第二季啟動的80項新的基因治療臨床試驗中，64%集中在腫瘤領域。這項數據表明，儘管面臨巨大的經濟障礙，該領域仍繼續專注於複雜適應症的臨床研究。

市場促進因素

支持性的法規結構和加快核准流程正在從根本上改變市場格局，加速新型治療方法的商業化進程。監管機構正在簡化生物製藥的複雜審查流程，例如FDA的「先進再生醫學」（RMAT）和「突破性治療方法」認定，並實施專門的認定方案，以縮短從臨床檢驗到患者用藥的時間。這種鼓勵創新的環境無疑增加了成功上市的案例數量，並展現了新興病毒載體和基因編輯技術的有效性。根據Fierce Pharma（2026年1月）報道，FDA在2024年核准了9種新的細胞和基因療法，創下該領域歷史新高。這些監管方面的突破透過提供清晰的商業化路徑和促進永續的行業參與，降低了未來專案的風險。

隨著監管政策的推進，生命科學研究領域的投資和資金籌措激增，為高成本的臨床開發和生產規模化提供了所需的資金，從而推動了市場擴張。生物製藥公司持續資金籌措以推進其研發管線，確保創新候選藥物能夠在經濟波動的影響下順利通過嚴格的測試階段。根據再生醫學聯盟（Alliance for Regenerative Medicine）2025年1月發布的數據，2024年全球在該領域的投資額達到152億美元，比上年成長30%。這筆資金流入支持治療方案多樣化且不斷擴展的生態系統。美國基因與細胞治療學會（ASGCT）在2025年11月報告稱，全球基因治療、細胞治療和RNA治療的研發管線包含超過3200項正在進行的臨床試驗。

市場挑戰

生產過程的高度複雜性及其相關成本是限制全球基因治療市場擴充性和商業性潛力的主要障礙。與小分子藥物不同，基因治療依賴複雜的生物過程，例如病毒載體的生產，本身就難以標準化和規模化。這種低的生產效率導致龐大的銷售成本，迫使企業設定高價，加重醫療預算負擔。因此，支付者通常會設定嚴格的報銷標準，限制患者獲得治療的機會，並減少維持進一步創新所需的收入。

此外，克服這些生產製造的挑戰需要大量的資本投入，這為研發公司帶來了嚴峻的財務環境。建造符合良好生產規範 (GMP) 的設施需要大量的前期投資，這會消耗原本可用於拓展產品線的資源。根據再生醫學聯盟 (Alliance for Regenerative Medicine) 統計，2024 年上半年該領域共籌集了約 109 億美元的資金。雖然這無疑是一筆巨款，但生物製造和供應鏈物流的高昂成本意味著大部分資金都用於營運支出，而非臨床研發。這正在減緩市場成長和產品商業化的整體步伐。

市場趨勢

目前，與合約研發生產機構 (CDMO) 拓展策略合作夥伴關係正有助於解決關鍵的生產瓶頸。外包給 CDMO 使研發公司能夠利用專業的病毒載體生產基礎設施，而無需承擔自建設施所需的大量資本成本。這項策略降低了技術風險，並透過既定的監管管道加快了臨床檢驗，使創新者能夠將資源集中於產品線開發而非程式工程。根據 Matika Biotechnology 於 2025 年 10 月發布的題為「Matika Biotechnology 崛起為領先的 CDMO」的新聞稿，該公司在 2025 年上半年獲得了 10 多個新的生產計劃，這反映出其正迅速採用外部生產模式來支持其不斷擴展的產品線。

同時，從體外給藥途徑到直接體內給藥途徑的轉變正在改變複雜組織標靶的治療模式。與僅限於易於獲取細胞的體外方法不同，直接體內給藥利用精密的載體來治療中樞神經系統等深部解剖部位。這種方法簡化了物流，並將基因療法的應用範圍擴展到以往難以治療的神經系統疾病。根據國際細胞與基因治療學會 (ISCT) 於 2025 年 1 月發布的題為《2024 年細胞與基因治療核准趨勢》的報告，Keviridy 的核准是一項突破性成就，它是首個能夠直接遞送至大腦的基因療法，證實了這種給藥途徑的實用性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球基因治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 載體類型（病毒載體、非病毒載體）
    • 給藥途徑（體內給藥、體外給藥）
    • 按類型分類的適應症（罕見疾病、癌症、神經系統疾病、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美基因治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲基因治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區基因治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲基因療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲基因治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球基因治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • REGENXBIO Inc.
  • Oxford Biomedica PLC.
  • Voyager Therapeutics Inc.
  • Human Stem Cells Institute
  • Dimension Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • bluebird bio, Inc.
  • Novartis AG
  • uniQure NV.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17109

The Global Gene Therapy Market is projected to expand from USD 7.54 Billion in 2025 to USD 13.02 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 9.53%. Gene therapy is characterized as a medical intervention that alters the genetic instructions within a patient's cells-by replacing, inactivating, or introducing genes-to treat or prevent diseases. This market growth is primarily fueled by the increasing prevalence of rare genetic disorders and chronic conditions, which generate an urgent need for long-lasting therapeutic solutions. Additionally, advancements in viral vector technologies and streamlined regulatory designations are accelerating the approval process, facilitating the transition of clinical research into commercially viable products.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.54 Billion
Market Size 2031USD 13.02 Billion
CAGR 2026-20319.53%
Fastest Growing SegmentNon-viral vectors
Largest MarketNorth America

Despite this progress, the high complexity of manufacturing and its associated costs present a significant barrier to market scalability and accessibility. These economic factors often lead to pricing structures that burden healthcare reimbursement systems and restrict patient adoption. According to the American Society of Gene & Cell Therapy, oncology indications comprised 64% of the 80 newly initiated gene therapy clinical trials in the second quarter of 2025. This statistic underscores the sector's continued clinical focus on complex indications, even in the face of substantial financial hurdles.

Market Driver

Supportive regulatory frameworks and expedited approval pathways are fundamentally transforming the market by accelerating the commercialization of novel treatments. Regulatory agencies have implemented specialized designations, such as the FDA's Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy status, which streamline the review process for complex biologic products and shorten the timeline between clinical validation and patient access. This pro-innovation environment has driven a tangible increase in successful market entries, effectively validating emerging viral vector and gene-editing technologies. According to Fierce Pharma in January 2026, the FDA approved nine new cell and gene therapies in 2024, setting a record for the sector; these regulatory milestones reduce risks for future programs and encourage sustained industrial participation by demonstrating a clear path to commercialization.

Concurrent with regulatory advancements, a surge in investment and funding for life sciences research is propelling market expansion by providing the essential capital needed for high-cost clinical development and manufacturing scale-up. Biopharmaceutical developers continue to secure significant financial backing to advance their pipelines, ensuring that innovative candidates can progress through rigorous testing phases despite broader economic fluctuations. According to the Alliance for Regenerative Medicine in January 2025, the sector attracted $15.2 billion in global investment in 2024, representing a 30% year-over-year increase. This influx of capital supports a diverse and expanding ecosystem of therapeutic options, with the American Society of Gene & Cell Therapy reporting in November 2025 that the global pipeline included more than 3,200 active clinical trials for gene, cell, and RNA therapies.

Market Challenge

The high complexity of manufacturing and the associated costs constitute a formidable barrier that directly impedes the scalability and commercial potential of the Global Gene Therapy Market. Unlike small-molecule drugs, gene therapies depend on intricate biological processes, such as viral vector production, which are inherently difficult to standardize and scale. This lack of manufacturing efficiency results in exorbitant Cost of Goods Sold (COGS), forcing companies to set high list prices that strain healthcare budgets. Consequently, payers often impose strict reimbursement criteria, which limits patient access and reduces the revenue potential necessary to sustain further innovation.

Furthermore, the capital-intensive nature of overcoming these manufacturing hurdles creates a challenging financial environment for developers. Establishing facilities that comply with Good Manufacturing Practice (GMP) requires massive upfront capital, draining resources that could otherwise fund pipeline expansion. According to the Alliance for Regenerative Medicine, the sector raised approximately $10.9 billion in investment during the first half of 2024. While this funding is substantial, the extreme costs associated with biomanufacturing and supply chain logistics mean that a significant portion of this capital is absorbed by operational expenses rather than clinical advancement, thereby slowing the overall rate of market growth and product commercialization.

Market Trends

The proliferation of strategic partnerships with Contract Development and Manufacturing Organizations (CDMOs) is currently addressing critical manufacturing bottlenecks. By outsourcing to CDMOs, developers gain access to specialized viral vector infrastructure without the prohibitive capital costs of building internal facilities. This strategy mitigates technical risks and expedites clinical validation through established regulatory pathways, allowing innovators to focus resources on pipeline development rather than process engineering. According to a press release from Matica Biotechnology in October 2025 titled 'Matica Biotechnology Emerges as the Go-To CDMO,' the company secured over 10 new manufacturing projects in the first half of 2025, reflecting the sector's rapid adoption of externalized production to support expanding pipelines.

Simultaneously, the shift from ex vivo to direct in vivo administration routes is transforming the therapeutic landscape for complex tissue targets. Unlike ex vivo methods, which are limited to accessible cells, direct in vivo delivery utilizes advanced vectors to treat deep anatomical sites such as the central nervous system. This approach simplifies logistics and extends the reach of gene therapy to previously untreatable neurological conditions. According to the International Society for Cell & Gene Therapy's January 2025 article 'Cell & Gene Therapy Approvals in 2024,' the approval of Kebilidi marked a milestone as the first gene therapy directly administered to the brain, confirming the viability of this administration route.

Key Market Players

  • REGENXBIO Inc.
  • Oxford Biomedica PLC.
  • Voyager Therapeutics Inc.
  • Human Stem Cells Institute
  • Dimension Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • bluebird bio, Inc.
  • Novartis AG
  • uniQure NV.

Report Scope

In this report, the Global Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Therapy Market, By Vector Type

  • Viral Vector
  • Non-Viral Vector

Gene Therapy Market, By Delivery Method

  • In-Vivo
  • Ex-Vivo

Gene Therapy Market, By Indication

  • Rare Diseases
  • Cancer
  • Neurological Diseases
  • Others

Gene Therapy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Therapy Market.

Available Customizations:

Global Gene Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 5.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 5.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Gene Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vector Type
    • 6.2.2. By Delivery Method
    • 6.2.3. By Indication
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gene Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Vector Type
        • 6.3.1.2.2. By Delivery Method
        • 6.3.1.2.3. By Indication
    • 6.3.2. Canada Gene Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Vector Type
        • 6.3.2.2.2. By Delivery Method
        • 6.3.2.2.3. By Indication
    • 6.3.3. Mexico Gene Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Vector Type
        • 6.3.3.2.2. By Delivery Method
        • 6.3.3.2.3. By Indication

7. Europe Gene Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vector Type
    • 7.2.2. By Delivery Method
    • 7.2.3. By Indication
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gene Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vector Type
        • 7.3.1.2.2. By Delivery Method
        • 7.3.1.2.3. By Indication
    • 7.3.2. France Gene Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vector Type
        • 7.3.2.2.2. By Delivery Method
        • 7.3.2.2.3. By Indication
    • 7.3.3. United Kingdom Gene Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vector Type
        • 7.3.3.2.2. By Delivery Method
        • 7.3.3.2.3. By Indication
    • 7.3.4. Italy Gene Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Vector Type
        • 7.3.4.2.2. By Delivery Method
        • 7.3.4.2.3. By Indication
    • 7.3.5. Spain Gene Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Vector Type
        • 7.3.5.2.2. By Delivery Method
        • 7.3.5.2.3. By Indication

8. Asia Pacific Gene Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vector Type
    • 8.2.2. By Delivery Method
    • 8.2.3. By Indication
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gene Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vector Type
        • 8.3.1.2.2. By Delivery Method
        • 8.3.1.2.3. By Indication
    • 8.3.2. India Gene Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vector Type
        • 8.3.2.2.2. By Delivery Method
        • 8.3.2.2.3. By Indication
    • 8.3.3. Japan Gene Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vector Type
        • 8.3.3.2.2. By Delivery Method
        • 8.3.3.2.3. By Indication
    • 8.3.4. South Korea Gene Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vector Type
        • 8.3.4.2.2. By Delivery Method
        • 8.3.4.2.3. By Indication
    • 8.3.5. Australia Gene Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vector Type
        • 8.3.5.2.2. By Delivery Method
        • 8.3.5.2.3. By Indication

9. Middle East & Africa Gene Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vector Type
    • 9.2.2. By Delivery Method
    • 9.2.3. By Indication
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Gene Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vector Type
        • 9.3.1.2.2. By Delivery Method
        • 9.3.1.2.3. By Indication
    • 9.3.2. UAE Gene Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vector Type
        • 9.3.2.2.2. By Delivery Method
        • 9.3.2.2.3. By Indication
    • 9.3.3. South Africa Gene Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vector Type
        • 9.3.3.2.2. By Delivery Method
        • 9.3.3.2.3. By Indication

10. South America Gene Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vector Type
    • 10.2.2. By Delivery Method
    • 10.2.3. By Indication
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gene Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vector Type
        • 10.3.1.2.2. By Delivery Method
        • 10.3.1.2.3. By Indication
    • 10.3.2. Colombia Gene Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vector Type
        • 10.3.2.2.2. By Delivery Method
        • 10.3.2.2.3. By Indication
    • 10.3.3. Argentina Gene Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vector Type
        • 10.3.3.2.2. By Delivery Method
        • 10.3.3.2.3. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gene Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. REGENXBIO Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Oxford Biomedica PLC.
  • 15.3. Voyager Therapeutics Inc.
  • 15.4. Human Stem Cells Institute
  • 15.5. Dimension Therapeutics, Inc.
  • 15.6. Bristol-Myers Squibb Company
  • 15.7. Sanofi
  • 15.8. F. Hoffmann-La Roche Ltd
  • 15.9. bluebird bio, Inc.
  • 15.10. Novartis AG
  • 15.11. uniQure NV.

16. Strategic Recommendations

17. About Us & Disclaimer